, Volume 16, Issue 9, pp 2383-2384
Date: 25 Jun 2009

Controversies in the Management of Hepatic Colorectal Metastases

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Colorectal cancer is the fourth leading cancer in the United States and ranks second in cancer-related deaths. Of the more than 140,000 new cases per year with this disease, 50% will develop liver metastases and approximately 30% will have metastatic disease confined to the liver. In the past, few patients who developed liver metastases were considered eligible for surgically directed therapies. With improved surgical techniques, reduced postoperative mortality, and better systemic therapy, outcomes have improved in recent years, with reported 5-year survival rates exceeding 50%. Given these results, an increasingly aggressive approach in the management of metastatic colorectal cancer has been advocated by many, including the expansion of indications for surgical therapy in these patients.

In this issue of Annals of Surgical Oncology, a series of review articles have been solicited to focus on important controversial topics in the management of hepatic colorectal metastases. In the firs ...

Statement Regarding Off-Label Pharmaceutical Information: This Educational Review may include information regarding the use of medications that may be outside the approved labeling for these products. Physicians should consult the current prescribing information for these products. Authors of Annals of Surgical Oncology educational reviews are provided at the time of article solicitation with this statement regarding off-label pharmaceutical information and research. Annals of Surgical Oncology Educational Reviews represent the journal’s commitment to the peer review and publication of high-quality research necessary to define the safety, toxicity, or effectiveness of potential therapeutic agents compared with conventional alternatives.
Disclosure information: Dr. Choti has served as a consultant for sanofi-aventis and Genentech.
An erratum to this article can be found at http://dx.doi.org/10.1245/s10434-009-0814-9